8-K Announcements
6Material company update
Mar 5, 2026·SEC
Material company update
Dec 3, 2025·SEC
Material company update
Nov 19, 2025·SEC
ZyVersa Therapeutics, Inc.(ZVSA)Earnings, Financials & Key Ratios
ZVSA•NASDAQ
$0.16
Price updated Jun 30, 2026
AboutZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.Show more
- Revenue$0
- EBITDA-$25M+99.7%
- Net Income-$24.95B-165.1%
- EPS (Diluted)-4.18+50.7%
ZVSA Price & Volume
ZyVersa Therapeutics, Inc. (ZVSA) stock price & volume — 10-year historical chart
Loading chart...
Pre-Revenue Clinical Development Drives Extreme Capital Erosion
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical trial failure
Key Thesis Takeaways
- ZyVersa Therapeutics operates as a high-risk, pre-commercial biotechnology entity characterized by negligible revenue generation and an aggressive, debt-financed clinical development strategy.
- The firm's reliance on substantial stock-based compensation, which peaked at $257.4 million in 2024Q3, complicates the assessment of operational efficiency while masking underlying cash burn.
- Investors should remain cautious as the company's negative equity position of $14.1 billion as of 2026Q1 and precarious liquidity profile suggest significant long-term solvency risks.
Verdict Logic
the company's current ratio of 0.03 as of 2026Q1 indicates severe liquidity constraints that may necessitate further dilutive financing to support ongoing clinical development.
ZVSA Growth Metrics
ZyVersa Therapeutics, Inc. (ZVSA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-20435.42%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM57.28%
Return on Capital
10 Years-28631.22%
5 Years-28631.22%
3 Years-42932.68%
Last Year-
ZVSA Recent Earnings
ZyVersa Therapeutics, Inc. (ZVSA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (50%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.22
—
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.43-43.3%
$0.30
Rev
—
—
Q4 2025
Nov 19, 2025Metric
Actual
Est
EPS
$0.15
—
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.46
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.22 | — |
| Q2 2026 | Mar 31, 2026 | $0.43vs $0.30-43.3% | — |
| Q4 2025 | Nov 19, 2025 | $0.15 | — |
| Q3 2025 | Aug 13, 2025 | $0.46 | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for ZyVersa Therapeutics, Inc. (ZVSA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.16 | $1.3B | -0.04 | — | — | — | — | |
| $3.37 | $367.98M | -1.68 | — | — | -70.79% | — | |
| $350.06 | $10.11B | -25.97 | -100% | — | -43.02% | — | |
| $38.51 | $7.91B | -13.90 | — | — | -68.16% | — | |
| $39.54 | $4.58B | -12.40 | — | — | -71.31% | — | |
| $2.05 | $123.66M | -3.66 | — | — | -0% | — |
Compare ZVSA vs Peers
ZyVersa Therapeutics, Inc. (ZVSA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ZVSA SEC Filings & Documents
ZyVersa Therapeutics, Inc. (ZVSA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ZVSA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ZVSA Frequently Asked Questions
ZyVersa Therapeutics, Inc. (ZVSA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is ZVSA profitable?
ZyVersa Therapeutics, Inc. (ZVSA) reported a net loss of $1.82B for fiscal year 2025.
Dividend & Returns
What is ZyVersa Therapeutics, Inc.'s free cash flow?
ZyVersa Therapeutics, Inc. (ZVSA) had negative free cash flow of $4.14B in fiscal year 2025, likely due to heavy capital investments.